Evolving landscape in aortic stenosis

Diagnosing Aortic Stenosis patients

It can be challenging confirming the AS severity and finding the optimal time to refer for further treatment.

2021 ESC/EACTS Treatment Guidelines

Explore the latest updates in aortic stenosis management and see the impact this may have on your referral decisions.

Today, 80 is the new 70

Transcatheter aortic valve implantation (TAVI) patients in their 70s and 80s showed comparable quality-of-life (QoL) improvements and clinical benefits1

View treatment and guidelines

Clinical evidence

Sustained durability of TAVI

Current durability evidence for TAVI valves supports the ESC/EACTS recommendation: TF-TAVI as preferred mode of intervention in patients ≥75 years of age**, as well as for additional patient groups < 75 years of age1

**Based on evaluation of clinical, anatomical and procedural factors

Mean Aortic Valve Gradient, PARTNER II A2†

TAVI has shown similar outcomes to surgery (SAVR) across key durability parameters:

  • With up to 5 years follow-up data of SAPIEN 3 TAVI versus SAVR2
  • Up to 10 years of evidence from Real-World observational studies3
See the evidence

Latest developments

2021 ESC/EACTS VHD Guidelines advocate for age-based assessment

Age has become a key factor in determining if a TAVI procedure is relevant for each AS patient. Find out more about the clinical evidence.

2021 ESC Congress Highlights

Watch a recorded symposium ‘The Future of TAVI’ by renowned TAVI experts from Europe.

Latest news and views from leading experts

Read the latest TAVI.today articles providing the latest information from leading experts and the industry on aortic stenosis and TAVI.

View all latest developments

Free resources for you and your patients

2021 ESC/EACTS Guidelines for Valvular Heart Disease

Receive your free ESC/EACTS Pocket Guidelines for VHD

Edwards TAVI study compendium

In-depth summary of the key Edwards Lifescience TAVI studies.

View all resources

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more

†Violin plots have become the new standard for representing echocardiographic data. Like box plots they show the distribution of the data, with the addition of the density of the data at different values.4

References:

1 Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.
2 Kodali SK, et al. Presentation at the Transcatheter Valve Therapies (TVT) Summit virtual event: TVT Connect 2020. Available at: https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients (accessed March 2021).
3 Sathananthan J, et al. Catheter Cardiovasc Interv. 2021;97(3):E431—E437.
4 Carron J. Violin Plots 101: Visualizing Distribution and Probability Density. Available at: https://mode.com/blog/violin-plot-examples (accessed April 2021)

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-0759 v6.0